Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Next Previous
X
Search
Trial Profile

A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amivantamab (Primary) ; Lazertinib (Primary) ; Osimertinib
  • Indications Brain metastases; Liver metastases; Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms MARIPOSA
  • Sponsors Janssen Research & Development; Janssen-Cilag

    • Most Recent Events

    • 04 Jun 2024 Results of secondary analysis from the phase 3 MARIPOSA study presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 31 May 2024 Results published in a Johnson & Johnson media release
    • 31 May 2024 According to a Johnson & Johnson media release, company announced new data from the Phase 3 MARIPOSA study demonstrating the benefit of first-line treatment with RYBREVANT (amivantamab-vmjw) in combination with lazertinib in patients with high-risk disease or clinical features.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top